Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)

#332

Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.

Aim(s): Impact of baseline Ki-67 index and other baseline characteristics on outcome was evaluated in a phase 3 trial of SU in pts with pancreatic NET.

Materials and methods: A total of 171 pts with pancreatic NET were randomized (1:1) in a double-blind trial of SU v. placebo (PBO). Ki-67 index was collected for exploratory analyses among those pts for whom it was available. Subgroup analyses of progression-free survival (PFS) by Ki-67 index and other baseline factors, including prior treatments (Tx), were performed.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Raymond E, Harmon C, Niccoli P, Metrakos P, Borbath I,

Keywords: Sunitinib, phase 3, pancreatic neuroendocrine tumor, Ki-67 index, prior treatment, prognostic factor,